In murine models of CHIP driven by Tet2, NLRP3 inhibitor MCC950 reduces IL-1β and atherosclerosis [44], and decreases fibrosis and hypertrophy following myocardial infarction [47]. Here, TET2 is linked to myocardial infarction.